The world’s leading CDMO, supporting your molecule across the full lifecycle

Lonza is the leading global CDMO partnering with ~1,500 biotechs worldwide, alongside pharma companies.  We combine scientific expertise, technological insight, process excellence and world-class development and manufacturing to support our customer from discovery to commercialization. Our integrated approach enables efficient progression through key milestones, helping bring life-saving and life-enhancing treatments to patients faster, and with reduced risk.

• Early de-risking with robust candidate selection and optimization to identify issues before IND

• Accelerated DNA-to-IND in as little as 6 months

• Proven, scalable expression systems enabling high titers and process consistency

• Experience across a range modalities, including complex formats such as ADCs

• Best-in-class ADC technology platforms such as GlycoConnect®, enabling next generation ADCs